↓ Skip to main content

Dove Medical Press

Article Metrics

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment

Overview of attention for article published in OncoTargets and therapy, June 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
22 Dimensions

Readers on

mendeley
29 Mendeley
Title
Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
Published in
OncoTargets and therapy, June 2012
DOI 10.2147/ott.s23273
Pubmed ID
Authors

Viktor Grünwald, Merseburger

Abstract

The landscape of renal cell carcinoma (RCC) treatment has changed dramatically during recent years. Bevacizumab/interferon, sunitinib, sorafenib, temsirolimus, everolimus, and pazopanib have been proven effective in metastatic RCC. Axitinib is a novel tyrosine kinase inhibitor, which inhibits the vascular endothelial growth factor receptor (VEGFR) at subnanomolar level. Based on this extraordinary VEGFR inhibition, axitinib is considered a next-generation agent. The recent AXIS trial reported on axitinib's efficacy in second line treatment of RCC, which led to its recent approval in the USA. This review focuses on the clinical efficacy of axitinib in RCC patients.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 3%
Unknown 28 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 17%
Other 3 10%
Professor > Associate Professor 3 10%
Student > Ph. D. Student 3 10%
Student > Doctoral Student 2 7%
Other 4 14%
Unknown 9 31%
Readers by discipline Count As %
Medicine and Dentistry 9 31%
Agricultural and Biological Sciences 5 17%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Biochemistry, Genetics and Molecular Biology 1 3%
Immunology and Microbiology 1 3%
Other 3 10%
Unknown 9 31%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 July 2012.
All research outputs
#11,092,630
of 12,475,053 outputs
Outputs from OncoTargets and therapy
#1,047
of 1,548 outputs
Outputs of similar age
#102,006
of 119,229 outputs
Outputs of similar age from OncoTargets and therapy
#8
of 11 outputs
Altmetric has tracked 12,475,053 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,548 research outputs from this source. They receive a mean Attention Score of 2.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 119,229 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.